5 related articles for article (PubMed ID: 38752926)
1. PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811.
Yu J; Saeed A
Chin Clin Oncol; 2024 Jun; ():. PubMed ID: 38859610
[No Abstract] [Full Text] [Related]
2. Durable pembrolizumab response in metastatic MSS ARID1A-mutant undifferentiated carcinoma of the esophagus.
Ijaz Z; Kahramangil D; Gera K; Sahin I
J Chemother; 2024 May; ():1-6. PubMed ID: 38752926
[TBL] [Abstract][Full Text] [Related]
3.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
4.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
5.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
